NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
Clinical Trials
6 trialsNCT05522491 2025-12-11
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06130254 2025-10-14
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04515836 2025-05-06
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Phase 2 Recruiting
NCT06739395 2024-12-18
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT03057145 2021-09-02
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed